Physician profile
Patrick B Alexander
NPI 1710009006
$16,021.35
in general payments reported to CMS, 2019-2025
43 companies · $2,133 in 2025
The $2,133 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,770 · 2020: $940 · 2021: $1,219 · 2022: $1,872 · 2023: $6,143 · 2024: $1,944 · 2025: $2,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,324 · Honoraria: $2,925 · Travel and Lodging: $872 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,324.09 |
| Honoraria | $2,925.00 |
| Travel and Lodging | $871.80 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,167.11 | 2019-2025 | Esprit, Amplatzer Amulet, Ensite Precision |
| Philips North America LLC | $4,368.82 | 2023-2025 | (6554) Periph Vasc Undiv, (Bs1) Peripheral Vascular Undivided, IV Other |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $760.85 | 2019-2025 | Lifevest |
| Medtronic, INC. | $673.60 | 2021-2025 | Protege Rx, Symplicity G3, In.Pact Admiral |
| Inari Medical, INC. | $509.18 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $477.08 | 2020-2022 | |
| Smith+Nephew, INC. | $456.44 | 2019-2023 | Pico 7 |
| Chiesi USA, INC. | $287.38 | 2020-2025 | Cleviprex, Kengreal |
| Cardiovascular Systems INC. | $267.12 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $260.33 | 2019-2023 | Lutonix Drug Coated Balloon, Venovo |
| Novartis Pharmaceuticals Corporation | $210.85 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $177.73 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.41 | 2019-2025 | Jardiance |
| Medtronic Vascular, INC. | $161.92 | 2019-2020 | |
| Amgen INC. | $160.17 | 2019-2025 | Repatha |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.